Pharma BD Deal Intelligence
Pfizer's ~$500M bet on Rinat's lead asset tanezumab ended in a 2021 FDA rejection and program termination — 15 years, zero approved products.
Full analysis, sources & comparables →Contract Pharma reported Pfizer's all-cash acquisition of Rinat for an estimated $500M, framing the deal as a major bet on CNS therapeutic proteins and…
Pfizer's 8-K press release announces the agreement to acquire Rinat Neuroscience, a CNS-focused biotech, framing it positively as advancing Pfizer's biologics…
FDA Joint Arthritis Advisory Committee voted 19-1 against tanezumab's risk management strategy in March 2021, and EMA refused marketing authorization in…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
CNS therapeutic proteins; all-cash; lead RN624 (tanezumab) for pain
Pfizer's ~$500M bet on Rinat's lead asset tanezumab ended in a 2021 FDA rejection and program termination — 15 years, zero approved products.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Rinat Neuroscience Corporation (this deal) | 2006 | $500M | 20 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2006 deals · Pfizer Inc. deals